Positive and negative future thinking fluency: A transdiagnostic meta-analysis of associations with psychopathology and hopelessness.

J Affect DisordMay 14, 2026 (epub)
Clinical ResearchPsychiatry

Matthias Pillny, Clementine J Edwards, Andrew MacLeod et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the associations between positive and negative future thinking fluency and hopelessness across various mental health conditions, involving 1726 participants. It found that clinical groups exhibited significantly reduced positive future thinking fluency (g = -0.88) compared to controls, while negative fluency showed no significant difference.

Key findings

  • Clinical groups had significantly reduced positive FFT fluency compared to controls (g = -0.88).
  • Negative FFT fluency did not differ significantly between clinical groups and controls (g = 0.25).
  • Hopelessness was associated with lower positive FFT fluency (r = -0.19) and higher negative FFT fluency (r = 0.15).

Why it matters

Understanding the patterns of future thinking fluency can help clinicians identify transdiagnostic processes in psychopathology, particularly in relation to hopelessness, which is a critical factor in suicidality.

Source

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.